Takeda Pharmaceutical Co ADR (TAK) concluded trading on Wednesday at a closing price of $14.72, with 3.6 million shares of worth about $52.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 13.32% during that period and on July 16, 2025 the price saw a loss of about -0.20%. Currently the company’s common shares owned by public are about 3.15B shares, out of which, 3.15B shares are available for trading.
Stock saw a price change of -2.71% in past 5 days and over the past one month there was a price change of -3.16%. Year-to-date (YTD), TAK shares are showing a performance of 9.52% which increased to 11.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.80 but also hit the highest price of $15.53 during that period. The average intraday trading volume for Takeda Pharmaceutical Co ADR shares is 2.17 million. The stock is currently trading -1.97% below its 20-day simple moving average (SMA20), while that difference is down -0.72% for SMA50 and it goes to 3.49% higher than SMA200.
Takeda Pharmaceutical Co ADR (NYSE: TAK) currently have 3.15B outstanding shares and institutions hold larger chunk of about 5.05% of that.
The stock has a current market capitalization of $46.33B and its 3Y-monthly beta is at 0.27. PE ratio of stock for trailing 12 months is 67.74, while it has posted earnings per share of $0.22 in the same period. Its PEG reads 1.44 and has Quick Ratio of 0.52 while making debt-to-equity ratio of 0.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TAK, volatility over the week remained 1.27% while standing at 1.05% over the month.
Analysts are in expectations that Takeda Pharmaceutical Co ADR (TAK) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 167.69% while it is estimated to increase by 20.49% in next year. EPS is likely to grow at an annualized rate of 47.03% for next 5-years, compared to annual growth of 11.40% made by the stock over the past 5-years.
Coverage by BofA Securities stated Takeda Pharmaceutical Co ADR (TAK) stock as a Buy in their note to investors on March 16, 2023, suggesting a price target of $20 for the stock. Stock get a Neutral rating from JP Morgan on April 19, 2021.
